Global Information would like to present a new market research report, "Dealmaking and Industry Outlook: Targeted Cancer Therapies" by Decision Resources.
In this report, we discuss the targeted cancer therapies market and its major players and provide insights from Decision Resources analysts on the current status and trends for these therapies. We provide an analysis of more than 350 deals that took place in the 12-month period from November 2008 through October 2009 and the business strategies that companies are deploying for future success. In addition, we include the insights we garnered from our survey of more than 200 U.S. medical oncologists about targeted therapies, existing unmet needs, and future opportunities in this arena.
Topics covered in this report include:
- The 2008 market for targeted oncology therapies was $27.1 billion, representing 40% of the total oncology market. Who are the major players in this market?
- Decision Resources analysts weighed in with their insights on the current status and future directions of targeted cancer therapies. What is limiting the commercial potential of tyrosine kinase inhibitors?
- In the 12-month period from November 2008 through October 2009, 378 deals were executed in the oncology therapy area. What deals involved targeted therapies?- Smart-Grid Sensor Opportunities in Electrical Transmission (Generation Site to Substations)
- We conducted a survey of 224 U.S. board-certified oncologists concerning current and future targeted therapies for cancer. What do surveyed oncologists say are the greatest unmet needs -and, thus, the greatest pharma company opportunities - in the targeted cancer therapies market?